A bootstrapped software company with over two decades of operating history expanded aggressively during the COVID-19 surge — only to see demand return to pre-pandemic levels within two years. Leadership was targeting a pivot to a scalable product platform, but the numbers told a different story.
A forensic P&L review revealed salary costs had risen 158% while revenue had declined 15%. Product revenue had fallen from 19% to just 8% of total income. Meanwhile, their planning scenarios projected 56% revenue growth alongside a proposed 45% cut to core service delivery staff — a mathematical impossibility.
A Strategic Gap Analysis was conducted to surface the disconnect between the company's narrative and its financial reality. A "Kill/Keep" framework was applied to rationalize the budget, protecting service delivery capacity — which accounted for over 90% of revenue — while eliminating non-revenue-generating roles the business could no longer sustain.
The outcome: a grounded, executable strategy focused on optimizing the profitable services engine and restoring financial stability.
An automation software company serving the academic life sciences sector had built a strong foothold in its core market but saw negative growth as conditions tightened. Through VOC feedback gathered in the field, a recurring request emerged: 21 CFR Part 11 compliance — the FDA standard governing electronic records in regulated R&D environments.
This was a telling signal. The company had been operating exclusively in the unregulated academic space and had not considered that a well-established, significantly larger market in mid-to-large pharma, CDMO, and CMO organizations was within reach — one where their existing platform had genuine merit, but where the absence of compliance capability had kept them out.
After a resource assessment confirmed the development investment was viable, the team built out the compliance features. Marketing then executed a two-phase campaign, first re-engaging existing clients who might benefit from the upgrade. Next, they launched a broader push into the pharma sector through updated collateral, booth materials, and a targeted social media campaign.
The result: a credible entry into a much larger, competitive market, opened up by paying close attention to what the field was already asking for.
A contract testing organization offering specialized services to the life sciences sector was facing a familiar challenge. Despite being the preferred provider to a key medical device client, valued for the depth and regulatory utility of their reports, some projects were being lost to a competitor based on turnaround time and poorly timed projects.
Further discovery revealed an additional complication. The client was undergoing a structural reorganization, with resources likely to be consolidated, leaving one division well-equipped for internal testing and another with, eventually, no testing capability at all.
Rather than competing on speed alone, a joint operating solution was proposed. Select client staff would be embedded within the testing facility and vice versa, giving the client direct visibility into project progress and addressing the turnaround concern. The arrangement also created a platform to train new personnel who could eventually support the under-resourced division. Structured around a monthly retainer, the model secured the full scope of the client's testing business and established a predictable recurring revenue stream. Mission-critical work remained with the client internally, while the higher volume of planned work flowed to the provider's team.
The result: A strengthened partnership, a resolved service complaint, and a scalable model that leadership subsequently directed the sales team to replicate across other key accounts.
A preclinical biotechnology startup was developing a diagnostics platform based on proprietary detection technology. The goal was to detect low‑abundance clinical biomarkers; however, the platform did not achieve the sensitivity required for reliable detection at clinically relevant levels.
The assay failed to meet sensitivity targets due to several compounding issues across the platform:
To address these challenges, a comprehensive technical assessment and redesign of the assay were conducted within the constraints of the existing platform.
Key steps included:
Results
The redesigned assay achieved an approximately 60‑fold improvement in sensitivity (limit of detection) while maintaining an acceptable coefficient of variation (CV), ensuring reproducibility.
This enabled reliable detection of the target biomarker at clinically relevant concentrations while preserving core platform characteristics, including time‑to‑result and detection modality.
A contract development, analytical and manufacturing organization, originally spun off from a larger firm, needed to shed its startup identity and establish a mature, independent brand aligned with its evolved service offering.
The engagement began with a series of leadership workshops to define the company's vision, differentiators, service categories, and messaging priorities. From there, a full website overhaul was executed, including a new hosting environment, redesigned architecture, and refreshed copy. A complete brand rollout followed: tri-folds, business cards, promotional materials and a custom 10×10 display booth.
With physical events postponed by the pandemic, the budget was redirected toward targeted digital campaigns in high-readership industry publications, virtual international event participation, LinkedIn video Q&As and white paper distribution. Site analytics were monitored continuously to track traffic sources, refine SEO, and measure ROI.
The result: a cohesive brand presence built for long-term credibility and launched efficiently under tight budget constraints.